Krystal Biotech (KRYS) Rating Increased to Hold at Zacks Investment Research

Krystal Biotech (NASDAQ:KRYS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

Separately, Ladenburg Thalmann Financial Services began coverage on Krystal Biotech in a research note on Wednesday, October 18th. They issued a “buy” rating and a $23.00 price objective on the stock.

Krystal Biotech (NASDAQ KRYS) traded down $0.09 during trading hours on Wednesday, reaching $10.52. The company’s stock had a trading volume of 24,900 shares, compared to its average volume of 58,767. Krystal Biotech has a 1-year low of $8.03 and a 1-year high of $11.98. The company has a market cap of $107.70 and a P/E ratio of -14.41.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 13th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.52). equities analysts forecast that Krystal Biotech will post -1.85 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Krystal Biotech stock. Highbridge Capital Management LLC acquired a new stake in shares of Krystal Biotech Inc (NASDAQ:KRYS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 300,000 shares of the company’s stock, valued at approximately $2,991,000. Highbridge Capital Management LLC owned 3.11% of Krystal Biotech as of its most recent SEC filing. 30.72% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Krystal Biotech (KRYS) Rating Increased to Hold at Zacks Investment Research” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3127539/krystal-biotech-krys-rating-increased-to-hold-at-zacks-investment-research.html.

Krystal Biotech Company Profile

Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.